Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: An open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers

Clinical Therapeutics

Volumn 28, Issue 1, 2006, Pages 110-115

  Piñeyro López, Alfredo ^a   Piñeyro Garza, Everardo ^a   Torres Alanís, Oscar ^a   Reyes Araiza, Raúl ^a   Gómez Silva, Magdalena ^a   Wacksman, Noemí ^a   Luján Rangel, Rubén ^a   Alberto, De Lago ^b   Trejo, Daniel ^b   González De La Parra, Mario ^b   Namur, Salvador ^b,c  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b Fundacion Liomont AC   (Mexico)

^c NONE   (Mexico)

Author keywords

Bioavailability; Bioequivalence; Human; Ketoconazole; Loratadine; Mass spectrometry; Pharmacokinetic

Indexed keywords

KETOCONAZOLE; LORATADINE; SENSIBIT;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MEXICO; RANDOMIZED CONTROLLED TRIAL; VITAL SIGN; VOLUNTEER;

EID: 32844462145     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.01.012     Document Type: Article

References (17)

1. Haria M., Fitton A., and Peters D.H. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders Drugs 48 1994 617 637
2. O'Neil M.J. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals 13th ed. 2001 Merck Research Laboratories Whitehouse Station, NJ 999
3. Available at Reents S., and Seymour J. Loratadine. Clinical Pharmacology 2000 [CD-ROM] Accessed February 16, 2004 2001 Gold Standard Multimedia Tampa, Fla
4. Accessed September 20, 2005 IMS HEALTH Report 2004 Interdata SA de CV Mexico City, Mexico Accessed September 20, 2005 Accessed September 20, 2005
5. Snoeck E., Van Peer A., and Heykants J. Pharmacokineticpharmacodynamic correlations of antihistamines Derendorf H. Hochhaus G. Handbook of Pharmacokinetic/Pharmacodynamic Correlation 1995 CRC Press Boca Raton, Fla 282 298
6. Brown N.J., and Jackson Roberts L II Histamine, bradykinin, and their antagonists Hardman J.G. Limbird L.E. Goodman & Gilman's The Pharmacological Basis o f Therapeutics 10th ed 2001 McGraw-Hill Medical Publishing Division New York, NY 653 655
7. Thummel K.E., and Shen D.D. Appendix II. Design and optimization of dosage regimens: Pharmacokinetic data Hardman J.G. Limbird L.E. Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed. 2001 McGraw-Hill Medical Publishing Division New York, NY 1976
8. Edinburgh, Scotland World Medical Association (WMA) Declaration of Helsinki Presented at the 52nd WMA General Assembly October 7, 2000
9. Kosoglou T., Salfi M., and Lim J.M. Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole orcimetidine Br J Clin Pharmacol 50 2000 581 589
10. Pineyro-Lopez A., Pineyro-Garza E., and Torres-Alanís O. Loratadine/Study no. 26-01 2004 Universidad Autónoma de Nuevo León Monterrey, Mexico
11. Sutherland F.C., de Jager A.D., and Badenhorst D. Sensitive liquid chromatography-tandem mass spec trometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma J Chromatogr A 914 2001 37 43
12. US Food and Drug Administration (FDA) Bioanalytical method validation. Guidance for industry 2001 FDA Washington, DC
13. Available at Ministry of Health of Mexico Comision Federal para la Proteccion contra Riesgos Sanitarios Federal Commission of Protection against Sanitary Risks Accessed July 15, 2005
14. US Food and Drug Administration In vivo bioequivalence guidances Pharmacopeial Forum 19 1993 6501 6508
15. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assess ing the equivalence of average bioavailability J Pharmacokinet Biopharm 15 1987 657 680
16. Chow S.-C. Liu J.-P. Statistical methods for average bioavailability and bioequivalence studies 2nd ed Design and Analysis of Bioavailability and Bioequivalence Studies 2000 Marcel Dekker New York, NY 79 124
17. revised and expanded Power and sample size determination Chow S.-C. Liu J.-P. Design and Analysis of Bioavailability and Bioequivalence Studies 2nd ed 2000 Marcel Dekker New York, NY 125 160